Onco-Tech Competition

Category of programs: Grants

New version on October 24th, 2018

Modifications in Section "Applicant eligibility, for General eligibility and eligibility to funding", in Section "Co-funding plan" as well as in Appendix 1 of these Guidelines.

DEADLINES

Submission of the letter of intent:
December 11, 2018

Submission of the complete application:
March 19, 2019

The FRQS reserves the right to modify the program schedule based on the volume of submitted projects.

FRQS - For document submission and for any administrative questions:

Manon Pelletier
Program manager

514-873-2114, ext. 1243
manon.pelletier@frq.gouv.qc.ca

MEDTEQ - For any questions about the co-funding plan (budget):

Djazia Liamini
Project manager

438-351-4674
djazia.liamini@medteq.ca

TransMedTech Institute (if applicable) - For support with the application:

Djazia Liamini
Project manager

438-351-4674
djazia.liamini@polymtl.ca

For any questions about Oncopole:

Charles Meunier
Project manager

cmeunier@oncopole.ca

PARTNERS AND BACKGROUND OF THE COMPETITION

Oncopole is a Québec hub for research, development and investment to accelerate the fight against cancer. Created in February of 2017, it is the product of a unique co-creation process led by the Fonds de recherche du Québec - Santé (FRQS) and made possible by an initial $15M investment from Merck Canada. Oncopole's mission is to act as a catalyst leveraging actions of key players in Québec's oncology and innovation research ecosystem. As a result, it aims to position the province as a leader in the field. Its priorities of action, namely research, entrepreneurship, commercialization and integration of innovation, as well as clinical relevance, are orchestrated in order to foster the mobilization of stakeholders, the discovery of innovative approaches to fight cancer and, ultimately, to generate a positive impact for the benefit of patients.

MEDTEQ's mission is to accelerate the development of innovative technologies serving clinicians and patients, their validation and integration in the healthcare system as well as their outreach both locally and internationally, by bringing together the complementary skills of industrial and institutional partners around those of the healthcare system.

The TransMedTech Institute's mission is to support the development of next-generation medical technologies for cardiovascular diseases, neuro-musculoskeletal diseases and cancer with the goal of facilitating their implementation in the healthcare system, training the next generation of medical technology professionals and making innovation in life sciences and engineering a source of wealth for society.

The Cancer Research Society (CRS) is a national, non-profit organization whose mission is to exclusively fund research into all types of cancer to prevent, detect and treat this disease. Every day in Canada's laboratories, researchers are working hard to make headway against cancer, a devastating disease. While they devote their careers to this fight, the CRS is committed to helping them with financial means so they can focus on their next discovery for tomorrow's patients.

With a shared vision of promoting Québec's medical technology innovations aimed at an oncology application, Oncopole, MEDTEQ, the TransMedTech Institute and CRS, in partnership with FRQS, are proud to join forces to launch this joint funding competition dedicated to accelerate the development, validation and marketing of new technologies, for the benefit of patients.

PROJECT ELIGIBILITY

Competition objectives	The purpose of the Onco-Tech competition is to fund cancer-related, high potential medical technology projects. In addition to the scientific innovation and excellence components, the project will have to demonstrate that it meets a clear clinical need and represents an obvious advantage over options currently available to patients. The funding will help develop the technology beyond the concept phase towards validation and technology transfer, thus facilitating access to funding from industry partners. Projects may include: • Diagnostic technologies (biomarkers and others) • Imaging and simulation (diagnostic, for surgery purposes, staff training) • Information technology and communication (mobile applications, mega-data applications, personalized medicine) • Rehabilitation technologies and other enabling technologies (bioMEMS, biomaterials, plastics/polymers and nanotechnologies) This list is not exhaustive; all technologies funded by MEDTEQ and the TransMedTech Institute are eligible for this competition. For any question concerning the eligibility of a technology, applicants are invited to contact Ms. Djazia Liamini of MEDTEQ (Djazia.Liamini@medteq.ca). Special attention will be put on the maturity stage of the proposed project. To be eligible, the candidate will have to show evidence of a well-substantiated discovery and have at least reached with this project the stage of "technology concept formulation" (Technology Readiness Level (TRL) of 2). Projects that have passed the stage of "verification in a representative environment" are not eligible (Technology Readiness Level (TRL) higher than 5). See **description** of TRLs and Appendix 3. Candidates are encouraged to work with an experienced partner in commercialization of innovation, either with their respective institution or with their university research commercialization company, when preparing their application.

APPLICANT ELIGIBILITY

Terms and conditions	As part of the Onco-Tech competition, the proposed projects and the research team members will have to comply with the rules and prerequisites of FRQS and MEDTEQ, in order to qualify for funding by all of the partners. Additional funding from the TransMedTech Institute could be included in the co-funding plan for eligible teams (see below – eligibility to TransMedTech Institute funding). **Structure of the research team** The research team must be composed of at least 2 people. It must include a maximum of two (2) Principal Investigators who will represent the project and manage its internal scientific direction according to the administrative conditions/requirements of the FRQS (see the Definitions of the Common General Rules section). The managing institution of the grant will be the employing institution of one of the Principal Investigators (Project leader). The research team may also include co-Investigators; a minimum of one (1) co-Investigator is required if there is only one Principal Investigator. In the case where the team includes two (2) Principal Investigators, no co-Investigator is required. The research team may also include collaborators, if applicable, though they will not have access to funds from this Competition. Collaborators must meet the definition found in the Definitions of the Common General Rules section. Investigators affiliated with federal, provincial or private laboratories are eligible as collaborators only. A Principal Investigator must demonstrate that he or she will be adequately involved to ensure the success of the project. In addition, all members of the team must demonstrate how they collaborate or intend to collaborate on the proposed research project and must specify how much time is allocated to the project or the level of involvement. **Postdoctoral fellows are not eligible for this program as principal investigators or co-investigators.** **PLEASE NOTE**: The addition or modification of Co-Investigators will be allowed between the submission of the letter of intent and the complete application. However, for the submission of the full application, the Principal Investigator(s) and the managing institution will have to remain the same as written in the letter of intent.

	Please ensure that research statuses of researchers added to a full application meet the definitions provided in the **Common General Rules**. **General eligibility** All individuals from an institution, research centers and institutes, or department affiliated to a Québec university, and associated with the project as a Principal Investigator, as well as Co-Investigators, must meet the definition of one of the following research statutes (see the Definitions section of the **Common General Rules**): ○ University researcher ○ Clinical University researcher **Eligibility to MEDTEQ funding** The proposed project must include an industrial partner with R&D and/or manufacturing activities in Québec. According to MEDTEQ rules (medteq.ca), this private partner will have to provide a minimum monetary contribution of 20% of the private funds for the co-funding plan (and other costs, see section: co-funding plan). **Eligibility to TransMedTech Institute funding (if applicable)** The TransMedTech Institute (TMTi) is an eligible co-funding partner as part of this program. Therefore, funding from TMTi can be added to the co-funding plan for eligible teams. To be eligible for funding from the TransMedTech Institute, the research team must include at least one Researcher (Principal Investigator or co-Investigator) who is a regular member of one of TransMedTech's founding institutions (Polytechnique Montréal, Université de Montréal, CHU Sainte-Justine, CHUM) and Jewish General Hospital). In addition, the research team must be composed of at least two Investigators from distinct fields (clinician, engineer, biologist, etc.) and involve relevant actors for the development and subsequent steps leading to the implementation of the technology (patient-partners, users, clinicians, administrators, etc.). Those interested in funding from the TransMedTech Institute should contact Djazia Lamini before submitting a project (djazia.liamini@medteq.ca); this will allow the TMTi team to start the procedure for verifying the eligibility to TMTi funding.
Professional order	Clinical researchers must prove that they are members in good standing of the professional order governing them in Québec, have a valid license to practice in Québec and have professional liability insurance.
Multiple applications	For this funding competition, an Investigator may only submit one project as a Principal Investigator.

	An Investigator can participate in up to 2 projects as a Co-Investigator. Therefore, an Investigator can participate in up to 3 projects under this program.
Employment affiliation and domicile	The Principal Investigator and the Co-Investigators must: • Be employed by a managing institution and be domiciled in Québec at the time the application is submitted (see section 2.1 of the **Common General Rules**) Collaborators can come from outside Québec, but no money can be transferred to them.
Ethics	The Principal Investigator and Co-Investigators must comply with the ethical regulations as defined in see sections 5.3 and 5.4 of the **Common General Rules**).
Basic training in research ethics	Basic training in research ethics is mandatory when the research project involves human subjects. Research on human beings involves: • Participation of human beings as subjects; • Use of human biological material (parts, products, tissues, cells, genetic material derived from the human body, from a living or deceased person); • Assisted reproduction activities or the use of embryos derived therefrom, within the meaning of the Act respecting clinical and research activities relating to assisted reproduction (R.S.Q. Chapter A-5.01); and/or • Use of administrative, scientific or descriptive data from human beings. This basic training consists of successfully completing levels 1 and 3 of the online tutorial set out by the *Ministère de la Santé et des Services sociaux du Québec*. Didacticiel en ligne. Principal Investigators and Co-Investigators must have successfully completed the basic training **before receiving their first payment.**

REQUIRED DOCUMENTS – LETTER OF INTENT

Transmission of documents:

This competition is managed by FRQS on behalf of the partners.

Missing documents or documents that do not comply with the competition rules and forms may result in the file being ineligible.

No extensions will be permitted. All forms not transmitted within the deadlines indicated will be automatically rejected.

The documents described below must be emailed to Manon Pelletier, program manager at FRQS (**manon.pelletier@frq.gouv.qc.ca**). Documents must be attached to one another as a single (1) PDF document. The CVs of the Principal Investigator(s), including detailed contributions, must be inserted one after the other into this PDF document.

The date and time of the transmission of the e-mail is proof of the date and time of the documents' filing.

Principal Investigator(s)	**NOTE: The letter of intent should be submitted to FRQS by the Principal Investigator managing the project and must include:** • **Letter of intent form** • **Canadian Common CV**, **Funding CV** version for FRQS (last update between June, 2016 and the competition deadline); • Detailed contributions (last update between June, 2016 and the competition deadline); consult the **Guidelines for the CV attachment file** available in the toolbox; • Letter of support from the TransMedTech Institute (if applicable) **Only investigators whose letters of intent were deemed eligible will be invited to submit a complete application** (see the **Evaluation** section). The FRQS will send an e-mail confirming the acceptance or rejection of the letter of Intent to each applicant.

REQUIRED DOCUMENTS – COMPLETE APPLICATION

Transmission of documents:

Missing documents or documents that do not comply with the competition rules and forms may result in the file being ineligible.

No extensions will be permitted. All forms not transmitted within the deadlines indicated will be automatically rejected.

The documents described below must be emailed to Manon Pelletier, program manager at the FRQS (**manon.pelletier@frq.gouv.qc.ca**). All documents must be included in a single (1) PDF document. The date and time of the transmission of the e-mail is proof of the date and time of the documents' filing.

The CVs of all Investigators, including detailed contributions, must be inserted one after the other into this PDF document.

Principal Investigator(s)	**NOTE: The complete application must be submitted to FRQS by the Principal Investigator of the managing institution (project leader) and must include:** • **Complete application form**

	• Canadian Common CV, **Funding CV** version for FRQS (last update between June 2016 and the competition deadline) • Detailed contributions (last update between June 2016 and the competition deadline); consult the **Guidelines for the CV attachment file** available the toolbox • Letter of support from the administrators of the institution or university department in which the research will be carried out, indicating the commitment towards the Principal Investigator (s) and the project (for each Principal Investigator); • Letters of support from the industrial partner(s) • Letters of support from collaborators, or partners, if any • For the industrial partner(s), the MEDTEQ membership form, if applicable for the company • For clinicians: a letter from the director of the clinical department or the dean of the faculty specifying the number of hours for which the applicant will be released from his/her clinical obligations to carry out the research project (only for clinicians who are not recipients of an FRQS career award).
Co-Investigators	• Canadian Common CV, **Funding CV** version for the FRQS (last update between June 2016 and the competition deadline) • Detailed contributions (last update between June 2016 and the competition deadline); consult the **Guidelines for the CV attachment file** available the toolbox • For clinicians: a letter from the director of the clinical department or the dean of the faculty specifying the number of hours for which the applicant will be released from his/her clinical obligations to carry out the research project (only for clinicians who are not recipients of an FRQS career award).

RESEARCH SITE

Choice of research location	An FRQS research centre or institute, an institution administered by the Ministère de la Santé et des Services sociaux (MSSS) or a Québec university.
Change of research location	The FRQS expects that the grantee will conduct his/her project at the same institution or university that initially endorsed the application throughout the entire grant period. The grantees who wish to change their research location must submit by e-mail an official request to the FRQS. The request must detail the reason(s)

	for the change and describe all possible consequences on the research project. University or institutional authorities must also notify the FRQS in writing once they have approved the change of location. Authorities of the new university or institution must notify the FRQS in writing that they accept to host the grantee.

DURATION OF THE GRANT

Term	**Two (2) years, non-renewable**
Funding Start Date	**July 2019**

AMOUNT OF THE GRANT

Amount	The total budget available for this competition includes $750,000 from Oncopole and $150,000 from CRS, combined with funding from MEDTEQ and other partners. The maximum contribution of Oncopole, combined with that of CRS, is $225,000 per project for two (2) years, for a maximum of $112,500 per project per year. Oncopole would like to fund 4 projects through this competition. **PLEASE NOTE**: although the funds invested in each project by Oncopole and CRS are for a fixed amount, matching of funds (by percentage) from other partners (MEDTEQ and TransMedTech (if applicable)) will vary depending on the industrial contribution (in accordance with standard rules of each organization). Appendix 1 shows 4 examples of eligible co-funding scenarios. Please note that the co-funding plans shown are for information only and have been established taking into account the minimum industrial contribution required by MEDTEQ. In the context of a larger industrial contribution, the matches by % will then correspond to larger amounts. Investigators are encouraged to contact MEDTEQ and TransMedTech (if applicable) to confirm their co-funding plan.
Co-funding plan **(See Appendix 1 for plans' examples)**	The appropriate type of co-funding plan will depend on: 1. Whether the project is eligible for funding from TransMedTech 2. Funding from all partners involved, based on eligibility 3. The **maturity stage** of the proposed project (TRL 2-3 vs. TRL 4-5). Although the type of co-funding plan is relevant for preparing the budget, it will not be taken into account when evaluating the project. The evaluation criteria

	remain focused on scientific excellence, the innovative character and the potential for commercialization of the proposed project (see "evaluation" section). **Funding partners, the percentages shown being relative to the total budget** A. **MEDTEQ (20% or 40%):** For projects that meet all the criteria described in the sections above, MEDTEQ will contribute up to: • 40% of the total budget for TRL 2-3 projects • 20% for TRL 4-5 projects • Up to a maximum of 500 000 $ per year per project B. **TransMedTech Institute (20%):** For eligible projects, the TransMedTech Institute will contribute 20% of the total budget, up to a maximum of $150,000 per project. C. **Industrial partner**: The industrial partner will make a monetary contribution of at least 20% of the private funds for the co-funding plan (see Appendix 1). In addition, the following expenses will also be covered by the industrial partner: • MEDTEQ membership fees, if necessary (to be checked before submitting the complete application) • MEDTEQ management costs (3% of the total budget) • Indirect research costs (IRC) applicable to the industrial monetary contribution **For TRL 4-5 projects:** • An in-kind contribution equivalent to 20% of the total budget for the proposed project will also be required
Management	The list of institutions that can administer funding from the FRQ is limited to the managing institutions recognized by the FRQ, including universities, CIUSSS, CISSS, some institutions of the healthcare network and colleges. The managing institution is the employing institution of the Principal Investigator (see section 6.2 of the **Common General Rules**).
Indirect research costs	An additional amount to the Onco-Tech grant will be paid on the portion of the funding from MEDTEQ, as well as the funding from the industrial partner, to cover indirect research costs (IRC). No additional amount to cover IRC will be paid for the funding from other partners (FRQS for the Oncopole, CRS and TMTi)..

ELIGIBLE EXPENSES

Eligible	**In addition to the list of eligible and non-eligible expenses detailed in Section 8 of the FRQ Common General Rules , the following expenses are eligible:** • Master's and doctoral awards or scholarships, postdoctoral fellowships and supplements, and, where applicable, salary for graduate students and postdoctoral fellows • Salaries for research assistants • Fees and reimbursement of travel expenses for research human subjects • Travel and accommodation costs (reasonable expenses) • Participation in congresses and conferences for up to 3% of the budget of the grant • Research material (including purchasing and housing for animals) and all other expenses required to carry out the research project, conditional upon adequate justification in the proposal • Reasonable and justified expenses (up to 10% of the total budget) related to purchasing equipment • Reasonable and justified expenses (up to 5% of the total budget) related to the acquisition of biological material from biobanks meeting the following requirements: ○ all retrospective (existing) bio-samples used for research funded under this program must originate from biological tissue banks registered or certified by the Canadian Tissue Repository Network (**CTRNet**) or Clinical Laboratory Improvement Amendments Act (**CLIA**) ○ all prospective (new) bio-samples financed under this program must be part of certified biological tissue banks or registered with **CTRNet** or **CLIA** Description of the CTRNet program for registration and certification of biobanks can be found **here**. • Expenditures related to the use of external specialized services • Equipment or platform usage fees • Costs related to knowledge translation and transfer to users (including other researchers, the general public, practitioners, decision makers and industry representatives) as appropriate for the research project
Not eligible:	• Remuneration of principal investigators, co-investigators and collaborators

	• All indirect expenditures related to layout organization or reorganization, facilities leasing and maintenance or the indirect costs covered by the host institution • Funds cannot be transferred outside Québec

EVALUATION

Letter of intent	The letter of intent is used to: • Establish the eligibility of the principal investigators • Verify the maturity stage for each project proposed • Assess the relevance of the application based on the program's objectives • Establish a review committee for the scientific and investment evaluation Only applicants with eligible letters of intent will be invited, by e-mail from FRQS, to submit a complete application.
Complete application	The applications will be evaluated by a review committee composed of experts from scientific (outside Québec) and industrial circles selected by FRQS and MEDTEQ based on their rules for the composition of review committees.

Evaluation criteria	**A. Scientific excellence (30%)** 1. Relevance of the project for cancer patients 2. Satisfactory justification of the TRL stage of maturity 3. Innovative nature of the technology(ies) 4. Clear objectives, based on a rigorous scientific approach and supported by the expertise of the research team 5. Appropriate methodological approaches 6. Integration of a multidisciplinary and intersectional approach 7. Expected results in line with the objectives of the competition **B. Research team (20%)** 1. Expertise and activities performed by the research team in the field 2. Expertise, quality and degree of involvement of the industrial partner in the project 3. Complementary relationship of the interdisciplinary and intersectional partners and their synergy 4. Training of young scientists and highly qualified professionals **C. Feasibility and potential risks (15%)** 1. Established realistic milestones/deliverables in the proposed budget a) Appropriate timeline (Gantt chart) b) Pre-determined parameters for their tracking (Go – No Go) 2. Identified risks and mitigation plan 3. Detailed budget a) Adequate justification of the financial needs along timeline b) Realistic budget planning in relation to milestones and deliverables **D. Commercial potential and impact (35%)** 1. Market needs and business opportunity a) Size of the market and how significant the need is b) Positioning of the project relative to care standards c) Originality and innovation: breakthrough innovation or incremental innovation d) Potential for adoption of technology by the end user and benefit for the patient 2. Competitive environment: positioning and competitive advantage 3. Potential for intellectual property (existing or future) and opportunity to create value 4. Impacts and anticipated benefits a) Québec-wide impact: potential for technology transfer and creation of a spin-off company; job creation b) International impact: outreach and contribution to positioning on the global market

RESEARCH RESULTS AND KNOWLEDGE TRANSFER

Submission of reports	In accepting the grant, the grantees agree to submit: • Annual financial reports and a final financial report at the deadlines indicated by the FRQS • An annual scientific report and a final report not more than 3 months after the end of the grant The funded team is committed to participating in mobilization activities of Oncopole and its partners, such as annual events or specific workshops.
Use and dissemination of the results by partners	Upon accepting the award, the investigator grants a non-exclusive and non-transferable license to the Onco-Tech co-funding partners (FRQS for the Oncopole, MEDTEQ, CRS and TMTi (if applicable)) of his/her copyright on the final scientific report without territorial limits, for an unlimited duration and for non-commercial purposes. This license allows the partners (FRQS for the Oncopole, MEDTEQ, CRS and TMTi (if applicable)) to reproduce, adapt, publish, translate and communicate the final scientific report to the public by any means available (conferences, websites, Facebook, Twitter, etc). The grantee guaranties to the partners (FRQS for the Oncopole, MEDTEQ, CRS and TMTi (if applicable)) that he/she holds all rights to enable his/her consent to the present copyright license. The Onco-Tech co-funding partners are committed to acknowledge the authors for any use of the material.
Knowledge mobilization	The FRQS encourages awardees to conduct and participate in knowledge mobilization activities (transfer, sharing, development, enhancement and dissemination) with practice settings and the general public, where such activities are relevant. Please read the document **Knowledge Mobilization** in the toolbox.

APPLICANT'S AGREEMENT

	In submitting his/her application, the applicant must: • Comply with the obligations outlined in the **Common General Rules**, the **Policy Regarding Open Access to Published Research Outputs** of the FRQS as well as the terms and conditions stipulated in the electronic form and the program rules • Submit additional files linked to the grant, if requested by the FRQS or MEDTEQ • Comply with the ethics and integrity standards outlined in the FRQS document **Standards en éthique de la recherche en santé humaine et d'intégrité scientifique** and in the **Policy for the Responsible Conduct of Research** of the Fonds de recherche du Québec • Authorize the FRQS, MEDTEQ, the CRS and the Oncopole executive management team (located at the Université de Montréal) to keep and use

all personal and scientific information provided in their application documents, in keeping with the terms and conditions outlined in the document entitled **Protection of personal and scientific information – FRQS** (see Appendix 2 of the present guide and this **statement**) and under the condition that the persons who have access to this information undertake to respect its confidentiality.

RESEARCH INSTITUTIONS AGREEMENT

The research institutions will provide:

- Functional laboratories and research facilities as well as basic equipment required to carry out the research project
- An environment respectful of the ethics and integrity standards outlined in the FRQS document **Standards en éthique de la recherche et d'intégrité scientifique** and in the **Policy for the Responsible Conduct of Research** of the Fonds de recherche du Québec

INTELLECTUAL PROPERTY

The grantees, and the institutions they are affiliated with, hold all copyrights for the intellectual property with respect to the original raw data, interim research works and funded project results, in keeping with the internal regulations for intellectual property of the institutions.

Within three (3) months following the announcement of the award, an agreement on the intellectual property has to be negotiated and signed between the managing institution and the industrial partner before funds can be released. This agreement will also be written to comply with the section "Use and dissemination of the results by partners" and Appendix 4 of the current competition guidelines.

Furthermore, since the Oncopole's mission is to mobilize oncology resources in Québec and because of Oncopole's federating vision, copyright holders from funded projects, including the institutions involved, are expected to remain involved and update the Oncopole so that the results of the co-funded project can be instrumental in the pursuit of Oncopole's objectives, with the ultimate objective of the results of each project helping the Québec community.

PARTNERS

Oncopole

MEDTEQ

TransMedTech Institute

Cancer Research Society (CRS)

Fonds de recherche du Québec – Santé (FRQS)

APPENDIX 1 – Examples of eligible co-funding plans for the Onco-Tech competition (including the maximum Oncopole–CRS contribution of $225,000)

For TRL 2-3 project:

		All partners, without TransMedTech (Type 1 Plan)		All partners (Type 2 Plan)	
Nature of funding	**Funding partner**	**% of project**	**Amount per project**	**% of project**	**Amount per project**
Public funds	TransMedTech Institute			20%[A]	$140,630
	MEDTEQ	40%[B]	$187,500	40%[B]	$281,250
Private funds	Oncopole	Fixed amnt[C]	$187,500	Fixed amnt[C]	$187,500
	Cancer Research Society	Fixed amnt[C]	$37,500	Fixed amnt[C]	$37,500
	Industrial partner	12% [MO]	$56,250	8% [MO]	$56,250
	Total	**100%**	**$468,750**	**100%**	**$703,130**

For TRL 4-5 project:

		All partners, without TransMedTech (Type 3 Plan)		All partners (Type 4 Plan)	
Nature of funding	**Funding partner**	**% of project**	**Amount per project**	**% of project**	**Amount per project**
Public funds	TransMedTech Institute			20%[A]	$140,630
	MEDTEQ	20%[B]	$93,750	20%[B]	$140,630
Private funds	Oncopole	Fixed amnt[C]	$187,500	Fixed amnt[C]	$187,500
	Cancer Research Society	Fixed amnt[C]	$37,500	Fixed amnt[C]	$37,500
	Industrial partner (monetary)	12% [MO]	$56,250	8% [MO]	$56,250
In-kind	Industrial partner (in-kind)	20% [CN]	$93,750	20% [CN]	$140,630
	Total	**100%**	**$468,750**	**100%**	**$703,130**

[A] For eligible projects, the TransMedTech Institute will contribute the equivalent to 20% of the total proposed budget, up to $150,000

[B] MEDTEQ will participate to funding project up to a maximum of $500,000 per year per project

Fixed amnt [C]: Fixed maximum amount for the funding by this partner

[MO] The industrial partner's minimum monetary contribution is established at a proportion of 20% of the private funds (Oncopole-CRS-Industrial partner) of the co-funding plan

[CN] In-kind contribution equivalent to 20% (of the total budget) will also be required from the industrial partner

Please note: The proposed amounts by type of co-funding plan are for information only and show the total budgets based on a minimum contribution of 20% (of the private funds) by the industrial partner. If there is a larger industrial contribution, the MEDTEQ and TransMedTech (if applicable, up to $150,000) amounts will vary depending on the proposed total budget (according to the rules of each organization).

The investigator can determine the budget available for the proposed project with the following steps:

1. Determine the budget required to achieve all deliverables for the project in 2 years.
2. According to the maturity stage of the project and its eligibility to TMTi funding, determine the type of co-funding plan appropriate for the proposed project using Appendix 1 of the guidelines.
3. Determine if the total budget corresponding to the co-funding plan is sufficient for the amount required as established in 1.
4. If the proposed project requires an amount equal or less to the budget of the co-funding plan in Appendix 1: when determining the detailed co-funding plan (Table to be filled) in the complete application form, simply write this amount at the bottom of the table as total and fill the rest of the table by dividing this amount between the different set rules of each partners for the competition (Fixed amount for Oncopole and CRS, % of the total for other partners) and then, divide the amount for each partner for each of the two years according to the project's needs.
5. Should the project require an amount superior to the total for the co-funding plan in Appendix 1, these options are also available:
    a. Find additional co-funding for the project (while this is not required for the Onco-Tech competition, this programme is compatible with other funding sources).
    b. Confirm an increased contribution for the industrial partner, which will be matched by the contribution from MEDTEQ and the contribution from TransMedTech (if applicable, up to $150,000).
    c. Following one of those options, it will be important to re-verify the co-funding plan and the contribution of each partner after filling the table for the co-funding plan in the complete application form and make sure that it complies to the rules from all co-funding partners.
6. Contact Djazia Liamini (djazia.liamini@medteq.ca) to confirm the validity of the co-funding plan with the corresponding budget.

Additional notes to help establish the co-funding plan for the proposed project:

- Funding from the TransMedTech Institute (if applicable) should represent 20% of the total budget requested, up to an amount of $150,000
- Funds from MEDTEQ should correspond to either 40% (TRL 2-3) or 20% (TRL 4-5) of the total funding requested, up to a maximum of $500,000 per year per project
- Only one industrial partner/SME is required to apply for Onco-Tech funding
- The monetary contribution of industrial partner(s)/SME(s) should represent, at minimum, 20% of the amount for private funds (Oncopole, CRS, industrial partner(s)) in the co-funding plan. This represents a minimum. Should this monetary contribution be increased, public funds (MEDTEQ and TransMedTech (if applicable, up to $150,000)) will match the industrial contribution; however, this increased monetary contribution will not be viewed as an asset for the evaluation of the proposed project
- For TRL 4-5 projects, an in-kind contribution will be considered for the evaluation of the involvement of the industrial partner (such contribution will be taken in account for up to 20% of the total budget). For TRL 2-3 projects, in kind contributions will not be recognized for evaluating the involvement of the industrial partner in the project (Only monetary contributions are considered for the application to Onco-Tech funding for TRL 2-3 projects)

APPENDIX 2

PROTECTION OF PERSONAL AND SCIENTIFIC INFORMATION

The forms completed under this competition are intended to collect personal and scientific information about you. This information will be used and kept by the Fonds de recherche du Québec – Santé (FRQS). FRQS will confidentially share this information and evaluation reports with the Oncopole Executive Management Team (whose offices are located at Université de Montréal) and its partners, MEDTEQ and CRS. The FRQS is subject to the Act respecting Access to documents held by public bodies and the Protection of personal information (CQLR, c. A-2.1) (Access Act).

The FRQS will submit complete applications as well as financial and scientific reports to each of the Competition Partners.

In this context, it is important to note that:

- The required personal and scientific information is used for the evaluation of grant applications, for the management of the Competition and allocated funds, and for the internal and external evaluation of the Competition. They are also used, aggregated with data from other candidates to generate statistics, inventories, evaluations and analyses related to the FRQS' mandate to promote and financially support health research.
- The information provided in these forms is mandatory for the analysis and evaluation of the grant applications. Failing to provide all the information required by the forms, the FRQS and MEDTEQ will not be able to review the application.
- Individuals who have access to the information collected by the FRQS are members of the evaluation committees (including external experts), consultants, and authorized FRQS staff. Individuals who have access to this information commit to respect its confidentiality.
- The content of the forms, both personal information and research information, is confidential and is disclosed only in accordance with this Appendix, the *Énoncé relatif à la protection des renseignements personnels et confidentiels des dossiers des candidats, candidates et titulaires d'un octroi,* with the consent of the data subject or the signatory of the application or in accordance with the provisions of the Access Act. with the consent of the person concerned or the person signing the application or in accordance with the provisions of the Access Act.
- Each individual has the right to access his/her personal information held by FRQS. He or she may require that any inaccurate, incomplete or equivocal personal information be modified. For further information on procedures for access, rectification or protection of personal information and access rights under the Access Act, the person responsible for Access Act to information at FRQS should be contacted.
- The three Fonds de recherche du Québec (Fonds de recherche du Québec – Nature et technologies, Fonds de recherche du Québec – Santé et Fonds de recherche du Québec – Société et culture) share their administrative services in accordance with the Act respecting the Ministère de l'Enseignement supérieur, de la Recherche, de la Science et de la Technologie (RLRQ, c. M-15.1.0.1). As a result, the FRQS may share the personal and scientific information provided on the forms with FRQNT and FRQSC staff whose collaboration is required to ensure optimal administration of funding programs and sound management of public funds.

For more information, please refer to the *Énoncé relatif à la protection des renseignements personnels et confidentiels des dossiers des candidats, candidates et titulaires d'un octroi.*

APPENDIX 3 - DESCRIPTION OF THE TECHNOLOGY READINESS LEVELS *



APPENDIX 4

SCIENTIFIC PUBLICATIONS AND PRESENTATIONS

1. For the following section, a scientific publication is a written publication submitted to an independent review comity. A scientific presentation is an oral presentation, by any medium, typically dedicated to an expert audience or an audience of end-users. Such scientific publications or presentations may be about results (final or interim) from activities or from research performed of the funded project

2. Results from the funded project should be made available for public dissemination by scientific publication or presentation within a reasonable time delay

3. The Oncopole, MCI, FRQS, CRS and MEDTEQ should be recognized as funding organizations in all scientific publications or presentations for the funded project. The text should specifically state:

   « This work was made possible by the financial support from MEDTEQ, the Cancer Research Society and from Oncopole, which, itself, received funding from Merck Canada inc. and from the Fonds de Recherche du Québec – Santé. »

4. Scientific publications or disseminations from a project funded by TMTi should specifically state:

   « This work benefited from the support of the TransMedTech Institute, which, in part, received funding from the Canada First Research Excellence Fund. »

5. Other types of disseminations dedicated to a scientific audience or a larger audience, should include a similar acknowledgement or the equivalent if it fits better the medium used (for example, verbal acknowledgement during an interview)

6. Scientifique publications or disseminations for the funded project should be reported to FRQS and to Oncopole's Executive Committee at the time of their dissemination or through the annual scientific report, at the latest